Concordia Jere Pharmaceutical-B (09966.HK): The Phase III clinical trial of the first-line treatment for HER2-positive advanced breast cancer with KN026 achieved its primary endpoint.

Zh tng cijng APP news, Kang Nng jirui zhyo-B (09966.HK) fb gnggo, y shyo jtun yuxin gngs (shyo jtun, gfn dim: 1093) fsh gngs shnghi jn mn t shngw kj yuxin gngs (jn mn t shngw) hzu kif de nn tu dnkng (shngpn mng: n n tu, ynf dim: KN026) linh zhsh yng du x t si (bi dngbnhngxng) (HB1801) yngy rnli biop shngzhng yns 2 (HER2) yngxng (HER2+) wnq rxin i yxin zhlio de III q lnchung ynji (ynji dim: KN026-003), jng dl shj jind wiyunhu (IDMC) pngg, chnggng ddo yxin shdng de zhyo zhngdin w jnzhn shngcn q (PFS), jigu jyu xinzhng de tngj xu h lnchung shungchng yy.